JP5619289B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5619289B2 JP5619289B2 JP2013530121A JP2013530121A JP5619289B2 JP 5619289 B2 JP5619289 B2 JP 5619289B2 JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013530121 A JP2013530121 A JP 2013530121A JP 5619289 B2 JP5619289 B2 JP 5619289B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- solvent
- minutes
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)(*1)C(*)(*)NC1c1ncc[n]1 Chemical compound CC(*)(*1)C(*)(*)NC1c1ncc[n]1 0.000 description 20
- DGGKXQQCVPAUEA-UHFFFAOYSA-N C(C1)C2NC1CCC2 Chemical compound C(C1)C2NC1CCC2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- FZGIOGLBCYSAGS-WCSIJFPASA-N C(c(cc1)ccc1-c1c[nH]c(C2NCCC2)n1)Oc(cc1)ccc1-c1c[nH]c([C@H]2NCCC2)n1 Chemical compound C(c(cc1)ccc1-c1c[nH]c(C2NCCC2)n1)Oc(cc1)ccc1-c1c[nH]c([C@H]2NCCC2)n1 FZGIOGLBCYSAGS-WCSIJFPASA-N 0.000 description 1
- KIBWZPHNDYFRFZ-UHFFFAOYSA-N C=Cc1c(C(O)=O)nccc1 Chemical compound C=Cc1c(C(O)=O)nccc1 KIBWZPHNDYFRFZ-UHFFFAOYSA-N 0.000 description 1
- FRCRNJHHZXJLMJ-ABLWVSNPSA-N CC(C(O[C@@H](C)c1ccccc1)=O)c(cccc1)c1F Chemical compound CC(C(O[C@@H](C)c1ccccc1)=O)c(cccc1)c1F FRCRNJHHZXJLMJ-ABLWVSNPSA-N 0.000 description 1
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C1=O)=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 1
- WYVJHHIVQNKMQT-UHFFFAOYSA-N CCNCC(c1ccc(COCc(cc2)ccc2C(CN)=O)cc1)=O Chemical compound CCNCC(c1ccc(COCc(cc2)ccc2C(CN)=O)cc1)=O WYVJHHIVQNKMQT-UHFFFAOYSA-N 0.000 description 1
- QVPBVAKLIWUEEJ-UHFFFAOYSA-N CN(C)C(C(O)=O)c1cnc(cccc2)c2c1 Chemical compound CN(C)C(C(O)=O)c1cnc(cccc2)c2c1 QVPBVAKLIWUEEJ-UHFFFAOYSA-N 0.000 description 1
- SKCUMFJFAWFXDL-UHFFFAOYSA-N CN(C)C1(Cc2ccccc2C1)C(O)=O Chemical compound CN(C)C1(Cc2ccccc2C1)C(O)=O SKCUMFJFAWFXDL-UHFFFAOYSA-N 0.000 description 1
- WSQJCEGRNUAEQD-JRTLPCBOSA-N CN(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)n2)c[nH]1)=O)c1ccccc1 Chemical compound CN(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)n2)c[nH]1)=O)c1ccccc1 WSQJCEGRNUAEQD-JRTLPCBOSA-N 0.000 description 1
- JCWUTEGWHABTTF-SECBINFHSA-N CN(C)[C@@H](C(O)=O)c(cccc1)c1F Chemical compound CN(C)[C@@H](C(O)=O)c(cccc1)c1F JCWUTEGWHABTTF-SECBINFHSA-N 0.000 description 1
- JCWUTEGWHABTTF-VIFPVBQESA-N CN(C)[C@H](C(O)=O)c1ccccc1F Chemical compound CN(C)[C@H](C(O)=O)c1ccccc1F JCWUTEGWHABTTF-VIFPVBQESA-N 0.000 description 1
- GOJLQSAREKTKPT-MRVPVSSYSA-N COC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound COC(N[C@@H](C(O)=O)c1ccccc1)=O GOJLQSAREKTKPT-MRVPVSSYSA-N 0.000 description 1
- IAQVBFWXJXRRMU-INIZCTEOSA-N COC([C@H](C(CC1)CCC11OCCO1)NC(OCc1ccccc1)=O)=O Chemical compound COC([C@H](C(CC1)CCC11OCCO1)NC(OCc1ccccc1)=O)=O IAQVBFWXJXRRMU-INIZCTEOSA-N 0.000 description 1
- OOIJOKDKOOJZJS-BYPYZUCNSA-N C[C@@H](C(O)=O)NC(N(C)C)=O Chemical compound C[C@@H](C(O)=O)NC(N(C)C)=O OOIJOKDKOOJZJS-BYPYZUCNSA-N 0.000 description 1
- MPFWQXMMIIJDNP-LRDDRELGSA-N C[C@@H](CC[C@H]1c2ncc(-c(cc3)ccc3Br)[nH]2)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CC[C@H]1c2ncc(-c(cc3)ccc3Br)[nH]2)N1C(OC(C)(C)C)=O MPFWQXMMIIJDNP-LRDDRELGSA-N 0.000 description 1
- QEIFWXUIJHFGPI-IMJSIDKUSA-N C[C@@H]([C@@H](C(O)=O)NC(OC)=O)O Chemical compound C[C@@H]([C@@H](C(O)=O)NC(OC)=O)O QEIFWXUIJHFGPI-IMJSIDKUSA-N 0.000 description 1
- GFRABURJAGGVIU-SUMWQHHRSA-N C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N(C)C)=O Chemical compound C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N(C)C)=O GFRABURJAGGVIU-SUMWQHHRSA-N 0.000 description 1
- QEIFWXUIJHFGPI-DMTCNVIQSA-N C[C@H]([C@@H](C(O)=O)NC(OC)=O)O Chemical compound C[C@H]([C@@H](C(O)=O)NC(OC)=O)O QEIFWXUIJHFGPI-DMTCNVIQSA-N 0.000 description 1
- KFXVSKIKSXJAJS-UHFFFAOYSA-N Cc(cc(cc1)C(CBr)=O)c1Br Chemical compound Cc(cc(cc1)C(CBr)=O)c1Br KFXVSKIKSXJAJS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/050138 WO2012039717A1 (en) | 2010-09-24 | 2010-09-24 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537905A JP2013537905A (ja) | 2013-10-07 |
| JP2013537905A5 JP2013537905A5 (enExample) | 2013-11-14 |
| JP5619289B2 true JP5619289B2 (ja) | 2014-11-05 |
Family
ID=43037168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530121A Expired - Fee Related JP5619289B2 (ja) | 2010-09-24 | 2010-09-24 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2619195A1 (enExample) |
| JP (1) | JP5619289B2 (enExample) |
| CN (1) | CN103249730A (enExample) |
| BR (1) | BR112013008148A2 (enExample) |
| CA (1) | CA2812699A1 (enExample) |
| EA (1) | EA201370078A1 (enExample) |
| MX (1) | MX2013002927A (enExample) |
| WO (1) | WO2012039717A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EP2616461A4 (en) | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| IN2014MN01547A (enExample) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| KR102330133B1 (ko) | 2013-12-04 | 2021-11-23 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체의 용도 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CA3055680A1 (en) | 2017-03-31 | 2018-10-04 | Syngenta Participations Ag | Fungicidal compositions |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| ES2967878T3 (es) | 2019-03-15 | 2024-05-06 | Medimmune Ltd | Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer |
| WO2024259085A2 (en) * | 2023-06-14 | 2024-12-19 | Alexion Pharmaceuticals, Inc. | Methods for the synthesis of complement factor d inhibitors and intermediates thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010034721A (ja) * | 2008-07-28 | 2010-02-12 | Fujitsu Ltd | パケットキャプチャ装置，パケットキャプチャ方法およびパケットキャプチャプログラム |
| EP2774927A1 (en) * | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-09-24 CA CA2812699A patent/CA2812699A1/en not_active Abandoned
- 2010-09-24 JP JP2013530121A patent/JP5619289B2/ja not_active Expired - Fee Related
- 2010-09-24 BR BR112013008148A patent/BR112013008148A2/pt not_active IP Right Cessation
- 2010-09-24 WO PCT/US2010/050138 patent/WO2012039717A1/en not_active Ceased
- 2010-09-24 EP EP10761101.4A patent/EP2619195A1/en not_active Withdrawn
- 2010-09-24 EA EA201370078A patent/EA201370078A1/ru unknown
- 2010-09-24 MX MX2013002927A patent/MX2013002927A/es not_active Application Discontinuation
- 2010-09-24 CN CN2010800703399A patent/CN103249730A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012039717A1 (en) | 2012-03-29 |
| CA2812699A1 (en) | 2012-03-29 |
| EA201370078A1 (ru) | 2013-11-29 |
| BR112013008148A2 (pt) | 2016-08-09 |
| MX2013002927A (es) | 2013-05-30 |
| CN103249730A (zh) | 2013-08-14 |
| EP2619195A1 (en) | 2013-07-31 |
| JP2013537905A (ja) | 2013-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5612660B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2013537905A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5697679B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5785189B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5847284B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5805763B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558557B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN102177141B (zh) | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 | |
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US20110237636A1 (en) | Hepatitis C Virus Inhibitors | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011511840A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TW201416363A (zh) | Ｃ型肝炎病毒抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130829 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140916 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5619289 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |